1. Bioptigen completes series A funding round, investment closes at $1.3 million

    Bioptigen, an optical technology company developing proprietary advances in the field of optical coherence tomography (OCT), announces the closing of its Series A round of funding. The round closed at $1.3 million and investors included the Piedmont Angel Network, the Inception Micro-Angel Fund and qualified individuals. Bioptigen will be The Piedmont Angel Network's PAN Two Fund's first investment. "We are exhilarated to have completed our first funding round with the support of the North Carolina angel investor community," stated Bioptigen's president and CEO Eric Buckland. "Over the past year, funded largely by phase I SBIR grants ...
    Read Full Article

    Login to comment.

  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. Quotes

    1. We are exhilarated to have completed our first funding round with the support of the North Carolina angel investor community.
  3. Topics Mentioned